aspartic acid has been researched along with Acute Disease in 74 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Latrunculin A microperfusion of the hippocampus induces acute epileptic seizures and long-term biochemical changes leading to spontaneous seizures." | 7.80 | Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. ( Loureiro, AI; Sierra-Marcuño, G; Sierra-Paredes, G; Soares-da-Silva, P; Wright, LC, 2014) |
| "Development of acute pancreatitis is associated with mitochondrial dysfunction and decreased cytosolic ATP level." | 5.91 | Sodium pyruvate improves the plasma amino acid profile in rats with L-arginine-induced acute pancreatitis. ( Manko, BO; Manko, VV; Ostapiv, RD; Zub, AM, 2023) |
| "Morphine pretreatment produced an increase in GABA levels and a decrease in glutamate levels in the first few minutes." | 5.35 | [Effect of a simple morphine system injection in some aminoacids in the anterior cingulate cortex during acute pain]. ( Hernández, L; Páez, X; Quiñones, B; Silva, E, 2008) |
| "Latrunculin A microperfusion of the hippocampus induces acute epileptic seizures and long-term biochemical changes leading to spontaneous seizures." | 3.80 | Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. ( Loureiro, AI; Sierra-Marcuño, G; Sierra-Paredes, G; Soares-da-Silva, P; Wright, LC, 2014) |
| "Impaired function of the central gamma-aminobutyric acid (GABA) system, which provides the brain's major inhibitory pathways, is thought to play an important role in the pathophysiology of anxiety disorders." | 3.76 | Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy. ( Drevets, WC; Grillon, C; Hasler, G; Shen, J; van der Veen, JW, 2010) |
| "Glutamine/glutamate ratio was significantly higher in ACC and POC in bipolar disorder, but not schizophrenia, compared with healthy control subjects." | 3.74 | Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. ( Cohen, BM; Jensen, JE; Lundy, M; Öngür, D; Prescot, AP; Renshaw, PF; Stork, C, 2008) |
| "Metabolite maps of choline-containing compounds, total creatine consisting of creatine and phosphocreatine, N-acetyl aspartate (NAA), and lactate were obtained in 23 patients with acute and subacute cerebral infarctions 1-35 days after onset of symptoms." | 3.69 | Metabolic changes in acute and subacute cerebral infarctions: findings at proton MR spectroscopic imaging. ( Heindel, W; Heiss, WD; Herholz, K; Kugel, H; Lackner, K; Lanfermann, H, 1995) |
| "Choline was significantly elevated in acute lesions compared with controls (P < 0." | 2.70 | Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis. ( Grodd, W; Klose, U; Mader, I; Melms, A; Naegele, T; Seeger, U; Weissert, R, 2001) |
| "We examined 5 patients with acute cerebral infarction using multi-voxel (section) MRS called 1H chemical shift imaging (CSI), or spectroscopic imaging (MRSI), during the first 24 hours from the onset." | 2.69 | [Clinical application of 1H nuclear magnetic resonance spectroscopy into patients with cerebral ischemia]. ( Asano, T, 1998) |
| "Development of acute pancreatitis is associated with mitochondrial dysfunction and decreased cytosolic ATP level." | 1.91 | Sodium pyruvate improves the plasma amino acid profile in rats with L-arginine-induced acute pancreatitis. ( Manko, BO; Manko, VV; Ostapiv, RD; Zub, AM, 2023) |
| "Psoriasis is a chronic inflammatory skin disease characterized by accelerated tumor necrosis factor-α (TNF-α) /interleukin (IL) -23/IL-17 axis, epidermal hyperproliferation, and dysregulated differentiation." | 1.62 | A Case of Autoimmune Hepatitis/Primary Biliary Cholangitis Overlap Syndrome during Treatment with Brodalumab for Generalized Pustular Psoriasis. ( Hoashi, T; Kanda, N; Okazaki, S; Saeki, H, 2021) |
| "Morphine pretreatment produced an increase in GABA levels and a decrease in glutamate levels in the first few minutes." | 1.35 | [Effect of a simple morphine system injection in some aminoacids in the anterior cingulate cortex during acute pain]. ( Hernández, L; Páez, X; Quiñones, B; Silva, E, 2008) |
| "Carbon monoxide (CO) exposure is a common cause of toxic brain damage, whereby effects range from transient neurological dysfunction to coma and death." | 1.33 | Carbon monoxide brain toxicity: clinical, magnetic resonance imaging, magnetic resonance spectroscopy, and neuropsychological effects in 9 people. ( Prockop, LD, 2005) |
| "The two patients with MELAS syndrome had large decreases of NAA signal (50% and 20% of normal values, respectively) from their occipital lobe lesions during the acute stroke-like episodes." | 1.29 | Reversible decreases in N-acetylaspartate after acute brain injury. ( Arnold, DL; De Stefano, N; Matthews, PM, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (18.92) | 18.7374 |
| 1990's | 20 (27.03) | 18.2507 |
| 2000's | 31 (41.89) | 29.6817 |
| 2010's | 7 (9.46) | 24.3611 |
| 2020's | 2 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Okazaki, S | 1 |
| Hoashi, T | 1 |
| Saeki, H | 1 |
| Kanda, N | 1 |
| Zub, AM | 1 |
| Ostapiv, RD | 1 |
| Manko, BO | 1 |
| Manko, VV | 1 |
| Igarashi, H | 1 |
| Suzuki, Y | 1 |
| Huber, VJ | 1 |
| Ida, M | 1 |
| Nakada, T | 1 |
| Sierra-Paredes, G | 1 |
| Loureiro, AI | 1 |
| Wright, LC | 1 |
| Sierra-Marcuño, G | 1 |
| Soares-da-Silva, P | 1 |
| Öngür, D | 1 |
| Jensen, JE | 1 |
| Prescot, AP | 1 |
| Stork, C | 1 |
| Lundy, M | 1 |
| Cohen, BM | 1 |
| Renshaw, PF | 1 |
| Schubert, GA | 1 |
| Poli, S | 1 |
| Schilling, L | 1 |
| Heiland, S | 1 |
| Thomé, C | 1 |
| Baron, JC | 1 |
| Cvoro, V | 1 |
| Wardlaw, JM | 3 |
| Marshall, I | 3 |
| Armitage, PA | 1 |
| Rivers, CS | 1 |
| Bastin, ME | 1 |
| Carpenter, TK | 1 |
| Wartolowska, K | 1 |
| Farrall, AJ | 1 |
| Dennis, MS | 2 |
| Silva, E | 2 |
| Quiñones, B | 1 |
| Páez, X | 1 |
| Hernández, L | 2 |
| Henry, LC | 1 |
| Tremblay, S | 1 |
| Boulanger, Y | 1 |
| Ellemberg, D | 1 |
| Lassonde, M | 1 |
| Gussew, A | 1 |
| Rzanny, R | 1 |
| Erdtel, M | 1 |
| Scholle, HC | 1 |
| Kaiser, WA | 1 |
| Mentzel, HJ | 1 |
| Reichenbach, JR | 1 |
| Hasler, G | 1 |
| van der Veen, JW | 1 |
| Grillon, C | 1 |
| Drevets, WC | 1 |
| Shen, J | 1 |
| Sullivan, KJ | 1 |
| Kissoon, N | 1 |
| Sandler, E | 1 |
| Gauger, C | 1 |
| Froyen, M | 1 |
| Duckworth, L | 1 |
| Brown, M | 1 |
| Murphy, S | 1 |
| Wang, WT | 1 |
| Lee, P | 1 |
| Yeh, HW | 1 |
| Smirnova, IV | 1 |
| Choi, IY | 1 |
| Michael, N | 1 |
| Erfurth, A | 1 |
| Ohrmann, P | 1 |
| Gössling, M | 1 |
| Arolt, V | 1 |
| Heindel, W | 2 |
| Pfleiderer, B | 1 |
| Nicoli, F | 1 |
| Lefur, Y | 1 |
| Denis, B | 1 |
| Ranjeva, JP | 1 |
| Confort-Gouny, S | 1 |
| Cozzone, PJ | 1 |
| Ameziane, N | 1 |
| Beillat, T | 1 |
| Verpillat, P | 1 |
| Chollet-Martin, S | 1 |
| Aumont, MC | 1 |
| Seknadji, P | 1 |
| Lamotte, M | 1 |
| Lebret, D | 1 |
| Ollivier, V | 1 |
| de Prost, D | 1 |
| Parrot, S | 1 |
| Cottet-Emard, JM | 1 |
| Sauvinet, V | 1 |
| Pequignot, JM | 1 |
| Denoroy, L | 1 |
| Fuller, RA | 1 |
| Westmoreland, SV | 2 |
| Ratai, E | 2 |
| Greco, JB | 2 |
| Kim, JP | 1 |
| Lentz, MR | 2 |
| He, J | 2 |
| Sehgal, PK | 2 |
| Masliah, E | 2 |
| Halpern, E | 1 |
| Lackner, AA | 2 |
| González, RG | 3 |
| Ratai, EM | 1 |
| Sakaie, K | 1 |
| Stengel, A | 1 |
| Neumann-Haefelin, T | 1 |
| Singer, OC | 1 |
| Neumann-Haefelin, C | 1 |
| Zanella, FE | 1 |
| Lanfermann, H | 2 |
| Pilatus, U | 1 |
| Frey, BN | 1 |
| Folgierini, M | 1 |
| Nicoletti, M | 1 |
| Machado-Vieira, R | 1 |
| Stanley, JA | 1 |
| Soares, JC | 1 |
| Kapczinski, F | 1 |
| Prockop, LD | 1 |
| Hall, NJ | 1 |
| Smith, VV | 1 |
| Harding, B | 1 |
| Pierro, A | 1 |
| Eaton, S | 1 |
| Rankins, D | 1 |
| Wellard, RM | 1 |
| Cameron, F | 1 |
| McDonnell, C | 1 |
| Northam, E | 1 |
| Lodi, R | 1 |
| Pierangeli, G | 1 |
| Tonon, C | 1 |
| Cevoli, S | 1 |
| Testa, C | 1 |
| Bivona, G | 1 |
| Magnifico, F | 1 |
| Cortelli, P | 1 |
| Montagna, P | 1 |
| Barbiroli, B | 1 |
| Berdeli, A | 1 |
| Gürkan, A | 1 |
| Emingil, G | 1 |
| Atilla, G | 1 |
| Köse, T | 1 |
| Melek, E | 1 |
| Ozyer, U | 1 |
| Erol, I | 1 |
| Alehan, F | 1 |
| Muhteşem Ağildere, A | 1 |
| Viola, A | 1 |
| Pagano, L | 1 |
| Laudati, D | 1 |
| D'Elia, R | 1 |
| D'Amico, MR | 1 |
| Ammirabile, M | 1 |
| Palmieri, S | 1 |
| Prossomariti, L | 1 |
| Ferrara, F | 1 |
| Singhal, AB | 1 |
| Benner, T | 1 |
| Vangel, M | 1 |
| Lee, V | 1 |
| Koroshetz, WJ | 1 |
| Schaefer, PW | 1 |
| Sorensen, AG | 1 |
| Kayabas, U | 1 |
| Alkan, A | 1 |
| Firat, AK | 1 |
| Karakas, HM | 1 |
| Bayindir, Y | 1 |
| Yetkin, F | 1 |
| Brubaker, RR | 1 |
| Dong, JM | 1 |
| Zhao, TR | 1 |
| Stasiński, T | 1 |
| Walczak-Mińko, R | 1 |
| Kostka-Wach, M | 1 |
| Biryńczyk, J | 1 |
| Kawczyńska, D | 1 |
| Wróz, M | 1 |
| Mathews, VP | 1 |
| Barker, PB | 2 |
| Blackband, SJ | 1 |
| Chatham, JC | 1 |
| Bryan, RN | 2 |
| Kugel, H | 1 |
| Herholz, K | 1 |
| Heiss, WD | 1 |
| Lackner, K | 1 |
| Gideon, P | 2 |
| Henriksen, O | 3 |
| Sperling, BK | 1 |
| Christiansen, P | 3 |
| Olsen, TS | 2 |
| Jørgensen, HS | 2 |
| Arlien-Søborg, P | 2 |
| De Stefano, N | 2 |
| Matthews, PM | 3 |
| Arnold, DL | 3 |
| Gyngell, ML | 1 |
| Busch, E | 1 |
| Schmitz, B | 1 |
| Kohno, K | 1 |
| Back, T | 1 |
| Hoehn-Berlage, M | 1 |
| Hossmann, KA | 1 |
| Gillard, JH | 1 |
| van Zijl, PC | 1 |
| Oppenheimer, SM | 1 |
| Singewald, N | 1 |
| Zhou, GY | 1 |
| Schneider, C | 1 |
| Defraigne, JO | 1 |
| Limet, R | 1 |
| Wild, J | 1 |
| Cannon, J | 1 |
| Lewis, SC | 1 |
| Dumka, VK | 1 |
| Tandan, SK | 1 |
| Tripathi, HC | 1 |
| Prakash, VR | 1 |
| Sager, TN | 1 |
| Laursen, H | 1 |
| Fink-Jensen, A | 1 |
| Topp, S | 1 |
| Stensgaard, A | 1 |
| Hedehus, M | 1 |
| Rosenbaum, S | 1 |
| Valsborg, JS | 1 |
| Hansen, AJ | 1 |
| Asano, T | 1 |
| Skvortsova, VI | 1 |
| Raevskiĭ, KS | 1 |
| Kovalenko, AV | 1 |
| Kudrin, VS | 1 |
| Malikova, LA | 1 |
| Sokolov, MA | 1 |
| Alekseev, AA | 1 |
| Gusev, EI | 1 |
| Gervais, FG | 1 |
| Xu, D | 1 |
| Robertson, GS | 1 |
| Vaillancourt, JP | 1 |
| Zhu, Y | 1 |
| Huang, J | 1 |
| LeBlanc, A | 1 |
| Smith, D | 1 |
| Rigby, M | 1 |
| Shearman, MS | 1 |
| Clarke, EE | 1 |
| Zheng, H | 1 |
| Van Der Ploeg, LH | 1 |
| Ruffolo, SC | 1 |
| Thornberry, NA | 1 |
| Xanthoudakis, S | 1 |
| Zamboni, RJ | 1 |
| Roy, S | 1 |
| Nicholson, DW | 1 |
| Narayanan, S | 1 |
| Francis, GS | 2 |
| Antel, JP | 2 |
| Helms, G | 1 |
| Stawiarz, L | 1 |
| Kivisäkk, P | 1 |
| Link, H | 1 |
| Wild, JM | 1 |
| Warlow, CP | 1 |
| Castillo, M | 1 |
| Smith, JK | 1 |
| Kwock, L | 1 |
| Yamamoto, Y | 1 |
| Kiyoi, H | 1 |
| Nakano, Y | 1 |
| Suzuki, R | 1 |
| Kodera, Y | 1 |
| Miyawaki, S | 1 |
| Asou, N | 1 |
| Kuriyama, K | 1 |
| Yagasaki, F | 1 |
| Shimazaki, C | 1 |
| Akiyama, H | 1 |
| Saito, K | 1 |
| Nishimura, M | 1 |
| Motoji, T | 1 |
| Shinagawa, K | 1 |
| Takeshita, A | 1 |
| Saito, H | 1 |
| Ueda, R | 1 |
| Ohno, R | 1 |
| Naoe, T | 1 |
| Demougeot, C | 1 |
| Garnier, P | 1 |
| Mossiat, C | 1 |
| Bertrand, N | 1 |
| Giroud, M | 1 |
| Beley, A | 1 |
| Marie, C | 1 |
| Mader, I | 1 |
| Seeger, U | 1 |
| Weissert, R | 1 |
| Klose, U | 1 |
| Naegele, T | 1 |
| Melms, A | 1 |
| Grodd, W | 1 |
| Abu-Duhier, FM | 1 |
| Goodeve, AC | 1 |
| Wilson, GA | 1 |
| Care, RS | 1 |
| Peake, IR | 1 |
| Reilly, JT | 1 |
| Köhler, FR | 1 |
| Ebel, J | 1 |
| Folbergrová, J | 1 |
| Norberg, K | 1 |
| Quistorff, B | 1 |
| Siesjö, BK | 1 |
| Danilenko, AM | 1 |
| Siianov, VS | 1 |
| Rodionov, VM | 1 |
| Fialko, VA | 1 |
| Sperling, B | 1 |
| Bosman, DK | 1 |
| Deutz, NE | 1 |
| Maas, MA | 1 |
| van Eijk, HM | 1 |
| Smit, JJ | 1 |
| de Haan, JG | 1 |
| Chamuleau, RA | 1 |
| O'Connor, J | 1 |
| Larsson, HB | 1 |
| Jensen, M | 1 |
| Frederiksen, J | 1 |
| Heltberg, A | 1 |
| Olesen, J | 1 |
| Janjua, NA | 1 |
| Mori, A | 1 |
| Hiramatsu, M | 1 |
| Simon, RP | 1 |
| Kühn, P | 1 |
| Koller, H | 1 |
| Kohn, P | 1 |
| Holzhey, P | 1 |
| Bodansky, O | 1 |
| Schwartz, MK | 1 |
| Nisselbaum, JS | 1 |
| Kaczmarczyk, G | 1 |
| Riedel, J | 1 |
| Udes, H | 1 |
| Reinhardt, HW | 1 |
| Iakushev, VS | 1 |
| Lifshits, RI | 1 |
| Slobodin, VB | 1 |
| Briukhin, GV | 1 |
| Huth, W | 1 |
| Dierich, C | 1 |
| von Oeynhausen, V | 1 |
| Seubert, W | 1 |
| Haskell, CM | 1 |
| Canellos, GP | 1 |
| Melzer, H | 1 |
| Weber, D | 1 |
| Wotzka, R | 1 |
| Nakane, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Glycine Augmentation in Carriers of a Mutation in the Gene Encoding Glycine Decarboxylase[NCT01720316] | Phase 2 | 2 participants (Actual) | Interventional | 2012-12-10 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine[NCT02304432] | Early Phase 1 | 2 participants (Actual) | Interventional | 2015-09-27 | Completed | ||
| Functional Near Infrared Spectroscopy as a Biomarker of Response in Patients With Post-concussion Syndrome Treated With Transcranial Magnetic Stimulation[NCT04568369] | 91 participants (Actual) | Interventional | 2020-05-02 | Active, not recruiting | |||
| Clinical Trial of Normobaric Oxygen Therapy in Acute Ischemic Stroke[NCT00414726] | Phase 2 | 85 participants (Actual) | Interventional | 2007-01-31 | Terminated (stopped due to Imbalance in deaths favoring control arm; deaths not attributed to treatment by the blinded external medical monitor.) | ||
| Mapping the Natural History of Traumatic Spinal Cord Injury in the Sensorimotor Cortex Using Functional Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging[NCT00790361] | 20 participants (Actual) | Observational | 2009-06-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Auditory evoked potentials amplitude: P50 ratio (S2/S1). Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | ratio (Number) |
|---|---|
| Auditory ERPs Amplitude (Deg) Baseline: Subject 2 | 44.51 |
| Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 2 | 35.67 |
Auditory evoked potentials amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2 amplitude; mismatch negativity (MMN) at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | microvolts (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 amplitude at fz | P300 amplitude at cz | P300 amplitude at pz | N100 amplitude at fz | N100 amplitude at cz | P200 amplitude at fz | P200 amplitude at cz | P50 S1 amplitude | P50 S2 amplitude | MMN amplitude at fz | MMN amplitude at cz | |
| Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 2 | 3.74 | 6.6 | 5.57 | -4.71 | -3.89 | 6.29 | 7.8 | 2.2 | 0.78 | -1.004 | -1.322 |
| Auditory ERPs Amplitude (Deg) Baseline: Subject 2 | -0.635 | 6.53 | 5.34 | -3.93 | -3.62 | 1.662 | 6.59 | 2.76 | 1.23 | -3.356 | -4.13 |
Auditory evoked potentials gamma: G40 hz phase locking at fz and cz; G20 hz phase locking response at fz and cz G30 hz phase locking response at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | microvolts squared (Number) | |||||
|---|---|---|---|---|---|---|
| G40 fz | G40 cz | G20 fz | G20 cz | G30 fz | G30 cz | |
| Auditory ERPs Gamma 6 Weeks of Glycine: Subject 2 | 0.255 | 0.29 | 0.107 | 0.108 | 0.177 | 0.242 |
| Auditory ERPs Gamma Baseline: Subject 2 | 0.135 | 0.168 | 0.023 | 0.03 | 0.19 | 0.163 |
Auditory evoked potentials latency: P300 at fz, cz, and pz); N100 at fz and cz); P200 at fz and cz. Participants were assessed at baseline and in week of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | msec (Number) | ||||||
|---|---|---|---|---|---|---|---|
| P300 latency at fz | P300 latency at cz | P300 latency at pz | N100 latency at fz | N100 latency at cz | P200 latency at fz | P200 latency at cz | |
| Auditory ERPs Latency (ms) 6 Weeks of Glycine: Subject 2 | 300.78 | 293 | 294.92 | 94 | 94 | 205 | 203 |
| Auditory ERPs Latency (ms) Baseline: Subject 2 | 279.3 | 279.3 | 279.3 | 97.66 | 91.8 | 197.27 | 193.4 |
Magnetic resonance spectroscopy GABA/Cr. Participants were assessed 1) pre-glycine treatment (baseline) and 2) in week 6 of open-label glycine treatment measured in posterior occipital cortex. (NCT01720316)
Timeframe: Baseline and week 6 of glycine
| Intervention | ratio (Number) | |
|---|---|---|
| Baseline GABA/Cr | Week 6 of glycine tx GABA/Cr | |
| Subject1: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine | 0.16 | 0.22 |
| Subject2: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine | 0.27 | 0.24 |
magnetic resonance spectroscopy - glutamate metabolite level. Participants were assessed 1) pre-glycine treatment and in week 6 of open-label glycine treatment. Measured in posterior occipital cortex. (NCT01720316)
Timeframe: baseline and week 6 of glycine
| Intervention | ratio (Number) | |
|---|---|---|
| Baseline brain glutamate/Cr ratio | Week 6 brain glutamate/Cr ratio | |
| Subject1: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine | 0.98 | 0.84 |
| Subject2: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine | 2.053 | 1.13 |
magnetic resonance spectroscopy: glycine/creatine ratio. Participants were assessed at 1) BASELINE PRE-GLYCINE TREATMENT: pre-glycine challenge drink, 60 minutes post challenge drink, 80 minutes post challenge drink, 100 minutes post challenge drink, and 120 minutes post challenge drink (0.4 g/kg up to max of 30 g); and 2) IN WEEK 6 OF OPEN-LABEL GLYCINE TREATMENT: pre-glycine dose, and 60 minutes, 80 minutes, 100 minutes and 120 minutes post daily dose of glycine. Measured in posterior occipital cortex (NCT01720316)
Timeframe: baseline (pre-challenge, 60, 80, 100, 120 minutes post-challenge), and week 6 of glycine (pre-dose and 60, 80, 100, 120 minutes post-dose
| Intervention | ratio (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline - pre-challenge drink | Baseline 60 minutes post challenge drink | Baseline 80 minutes post challenge drink | Baseline 100 minutes post challenge drink | Baseline 120 minutes post challenge drink | Week 6 of glycine - pre-glycine dose | Week 6 of glycine - 60 minutes post glycine dose | Week 6 of glycine - 80 minutes post glycine dose | Week 6 of glycine - 100 minutes post glycine dose | Week 6 of glycine - 120 minutes post glycine dose | |
| Subject 2:Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine | 0.5691 | 0.3918 | 0.6428 | 0.6363 | 0.9559 | 0.3235 | 0.3807 | 0.5591 | 0.4142 | 0.3545 |
| Subject1: Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine | 0.2558 | 0.6157 | 0.6631 | 0.5938 | 0.6953 | 0.6573 | 0.2983 | 0.4577 | 0.5751 | 0.3842 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within and after each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPRS at baseline | BPRS at 2 weeks intervention 1 | BPRS at 4 weeks intervention 1 | BPRS at 6 weeks intervention 1 | BPRS, end of washout1 | BPRS at 2 weeks intervention 2 | BPRS at 4 weeks intervention 2 | BPRS at 6 weeks intervention 2 | BPRS, end of washout2 | BPRS at 2 weeks open label | BPRS at 4 weeks open label | BPRS at 6 weeks open label | BPRS, end of washout3 | |
| Glycine, Then Placebo | 39 | 38 | 32 | 21 | 22 | 37 | 31 | 37 | 32 | 23 | 22 | 21 | 19 |
| Placebo, Then Glycine | 46 | 38 | 39 | 28 | 34 | 32 | 20 | 23 | 24 | 20 | 18 | 19 | 23 |
Clinical Global Impression (CGI) severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT01720316)
Timeframe: CGI at baseline and at 2 weeks, 4 weeks, and 6 weeks per treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI severity score at baseline | CGI severity score at 2 weeks intervention 1 | CGI severity score at 4 weeks intervention 1 | CGI severity score at 6 weeks intervention 1 | CGI severity score, end of washout1 | CGI severity score at 2 weeks intervention 2 | CGI severity score at 4 weeks intervention 2 | CGI severity score at 6 weeks intervention 2 | CGI severity score, end of washout2 | CGI severity score at 2 weeks open label | CGI severity score at 4 weeks open label | CGI severity score at 6 weeks open label | CGI severity score, end of washout3 | |
| Glycine, Then Placebo | 4 | 4 | 3 | 2 | 2 | 4 | 4 | 4 | 4 | 3 | 3 | 2 | 2 |
| Placebo, Then Glycine | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 |
Clinical Global Impression (CGI) therapeutic effect scores measure degree of improvement as marked (1), moderate (5), minimal (9) or unchanged/worse (13). (NCT01720316)
Timeframe: at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | score (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI therapeutic effect at 2 weeks intervention 1 | CGI therapeutic effect at 4 weeks intervention 1 | CGI therapeutic effect at 6 weeks intervention 1 | CGI therapeutic effect, end of washout1 | CGI therapeutic effect at 2 weeks intervention 2 | CGI therapeutic effect at 4 weeks intervention 2 | CGI therapeutic effect at 6 weeks intervention 2 | CGI therapeutic effect, end of washout2 | CGI therapeutic effect at 2 weeks open label | CGI therapeutic effect at 4 weeks open label | CGI therapeutic effect at 6 weeks open label | CGI therapeutic effect, end of washout3 | |
| Glycine, Then Placebo | 13 | 5 | 5 | 5 | 13 | 13 | 13 | 13 | 5 | 5 | 1 | 1 |
| Placebo, Then Glycine | 5 | 5 | 5 | 5 | 13 | 5 | 5 | 5 | 1 | 1 | 1 | 1 |
Hamilton Depression Scale measures severity of depression symptoms. The sum of ratings for 9 depression symptoms are measured on a scale from 0-2 with 0 meaning no symptoms and 2 meaning some level of severity of that specific symptom. The rating for 1 depression symptom is measured on a scale from 0-3 with 0 meaning no symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms are measured on a scale from 0-4 with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depression symptoms at baseline | Depression symptoms at 2 weeks intervention 1 | Depression symptoms at 4 weeks intervention 1 | Depression symptoms at 6 weeks intervention 1 | Depression symptoms, end of washout1 | Depression symptoms at 2 weeks intervention 2 | Depression symptoms at 4 weeks intervention 2 | Depression symptoms at 6 weeks intervention 2 | Depression symptoms, end of washout2 | Depression symptoms at 2 weeks open label | Depression symptoms at 4 weeks open label | Depression symptoms at 6 weeks open label | Depression symptoms, end of washout3 | |
| Glycine, Then Placebo | 18 | 17 | 11 | 3 | 1 | 19 | 5 | 7 | 3 | 2 | 2 | 1 | 2 |
| Placebo, Then Glycine | 12 | 5 | 5 | 0 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
Plasma glycine levels; normal range is 122-467 nM/mL (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine
| Intervention | nM/mL (Number) | |||
|---|---|---|---|---|
| Baseline | Glycine double-blind | Placebo | Glycine open-label | |
| Glycine Then Placebo | 216 | 410 | 194 | 516 |
| Placebo Then Glycine | 271 | 761 | 347 | 634 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of ratings for 7 symptoms of mania is measured on a scale from 0-4 and the sum of 4 symptoms of mania is measured on a scale from 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manic symptoms at baseline | Manic symptoms at 2 weeks intervention 1 | Manic symptoms at 4 weeks intervention 1 | Manic symptoms at 6 weeks intervention 1 | Manic symptoms, end of washout1 | Manic symptoms at 2 weeks intervention 2 | Manic symptoms at 4 weeks intervention 2 | Manic symptoms at 6 weeks intervention 2 | Manic symptoms, end of washout2 | Manic symptoms at 2 weeks open label | Manic symptoms at 4 weeks open label | Manic symptoms at 6 weeks open label | Manic symptoms, end of washout3 | |
| Glycine, Then Placebo | 4 | 1 | 0 | 0 | 0 | 17 | 0 | 2 | 2 | 1 | 0 | 0 | 0 |
| Placebo, Then Glycine | 7 | 7 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution; standard deviation of 10. Only overall composite score is entered. (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine
| Intervention | units on a scale (Number) | |
|---|---|---|
| Participant 1 | Participant 2 | |
| Baseline | 45 | 48 |
| Composite Score on Glycine, Double-blind | 52 | 52 |
| Composite Score on Glycine, Open-label | 49 | 46 |
| Composite Score on Placebo | 52 | 55 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms are measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period and after each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive symptoms at baseline | Positive symptoms at 2 weeks intervention 1 | Positive symptoms at 4 weeks intervention 1 | Positive symptoms at 6 weeks intervention 1 | Positive symptoms, end of washout1 | Positive symptoms at 2 weeks intervention 2 | Positive symptoms at 4 weeks intervention 2 | Positive symptoms at 6 weeks intervention 2 | Positive symptoms, end of washout2 | Positive symptoms at 2 weeks open label | Positive symptoms at 4 weeks open label | Positive symptoms at 6 weeks open label | Positive symptoms, end of washout3 | |
| Glycine, Then Placebo | 13 | 12 | 9 | 8 | 7 | 12 | 11 | 14 | 14 | 9 | 9 | 7 | 7 |
| Placebo, Then Glycine | 19 | 20 | 19 | 13 | 13 | 12 | 10 | 11 | 11 | 8 | 7 | 8 | 8 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
Auditory evoked potential amplitude: P50 ratio (P50 S2/S1) (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | ratio (Number) | |
|---|---|---|
| P50 ratio: Baseline | P50 ratio: Week 8 of DCS | |
| First Open Label DCS | 44.51 | 30 |
Auditory evoked potential amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2; mismatch negativity (MMN) at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | microvolts (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 at fz: Baseline | P300 at cz: Baseline | P300 at pz: Baseline | N100 at fz: Baseline | N100 at cz: Baseline | P200 at fz: Baseline | P200 at cz: Baseline | P50 S1: Baseline | P50 S2: Baseline | MMN at fz: Baseline | MMN at cz: Baseline | P300 at fz: Week 8 of DCS | P300 at cz: Week 8 of DCS | P300 at pz: Week 8 of DCS | N100 at fz: Week 8 of DCS | N100 at cz: Week 8 of DCS | P200 at fz: Week 8 of DCS | P200 at cz: Week 8 of DCS | P50 S1: Week 8 of DCS | P50 S2: Week 8 of DCS | MMN at fz: Week 8 of DCS | MMN at cz: Week 8 of DCS | |
| First Open Label DCS | -0.635 | 6.529 | 5.340 | -3.926 | -3.615 | 1.662 | 6.591 | 2.759 | 1.23 | -3.356 | -4.130 | 3.030 | 6.810 | 6.620 | -3.260 | -3.940 | 8.200 | 8.160 | 1.36 | 0.4 | -3.330 | -1.540 |
Auditory evoked potential gamma: G40 hz phase locking at fz and cz; G30 hz phase locking at fz and cz; G20 hz phase locking at fz and cz (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | microvolts squared (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G40 hz phase locking at fz: Baseline | G40 hz phase locking at cz: Baseline | G30 hz phase locking at fz: Baseline | G30 hz phase locking at cz: Baseline | G20 hz phase locking at fz: Baseline | G20 hz phase locking at cz: Baseline | G40 hz phase locking at fz: Week 8 of DCS | G40 hz phase locking at cz: Week 8 of DCS | G30 hz phase locking at fz: Week 8 of DCS | G30 hz phase locking at cz: Week 8 of DCS | G20 hz phase locking at fz: Week 8 of DCS | G20 hz phase locking at cz: Week 8 of DCS | |
| First Open Label DCS | 0.135 | 0.168 | 0.190 | 0.163 | 0.023 | 0.030 | 0.344 | 0.381 | 0.168 | 0.19 | 0.01 | -0.01 |
Auditory evoked potential latency: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | msec (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 at fz: Baseline | P300 at cz: Baseline | P300 at pz: Baseline | N100 at fz: Baseline | N100 at cz: Baseline | P200 at fz: Baseline | P200 at cz: Baseline | P300 at fz: Week 8 of DCS | P300 at cz: Week 8 of DCS | P300 at pz: Week 8 of DCS | N100 at fz: Week 8 of DCS | N100 at cz: Week 8 of DCS | P200 at fz: Week 8 of DCS | P200 at cz: Week 8 of DCS | |
| First Open Label DCS | 279.297 | 279.297 | 279.297 | 97.656 | 91.797 | 197.266 | 193.359 | 294.920 | 294.000 | 294 | 87.9 | 88.000 | 212.890 | 212.000 |
Proton magnetic resonance spectroscopy at 4T: brain glycine/CR ratio. Participants were assessed at baseline (pre-glycine challenge dose and 60, 80, 100 and 120 minutes post glycine dose) and in week 8 of of open-label DCS treatment: pre-DCS dose, and 60, 80, 100 and 120 minutes post DCS dose. Measured in posterior occipital cortex. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | ratio (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Baseline at 60 minutes | Baseline at 80 minutes | Baseline at 100 minutes | Baseline at 120 minutes | Week 8 of DCS: Baseline | Week 8 of DCS: 60 minutes | Week 8 of DCS: 80 minutes | Week 8 of DCS: 100 minutes | Week 8 of DCS: 120 minutes | |
| Open Label DCS | 0.41245 | 0.50375 | 0.65295 | 0.61505 | 0.8256 | 0.10977 | 0.248885 | 0.32609 | 0.32052 | 0.312155 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline BPRS | 2 weeks BPRS | 4 weeks BPRS | 6 weeks BPRS | 8 weeks BPRS | 10 weeks BPRS | 12 weeks BPRS | 14 weeks BPRS | 16 weeks BPRS | 18 weeks BPRS | 20 weeks BPRS | 22 weeks BPRS | 24 weeks BPRS | |
| First Open Label DCS | 37 | 25 | 26 | 24 | 24.5 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 31.5 | 30.5 | 28 | 25.5 | 26 | 26.5 | 26 | 25.5 | 28.5 | 27 | 25 | 24.5 | 26.5 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline BPRS for first intervention | 2 weeks BPRS for first intervention | 4 weeks BPRS for first intervention | 6 weeks BPRS for first intervention | Baseline BPRS for second intervention | 2 weeks BPRS for second intervention | 4 weeks BPRS for second intervention | 6 weeks BPRS for second intervention | |
| DCS First, Then Placebo | 26 | 25 | 25 | 26 | 39 | 45 | 45 | 38 |
| Placebo First, Then DCS | 29 | 35 | 33 | 35 | 36 | 30 | 27 | 28 |
CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline CGI | 2 weeks CGI | 4 weeks CGI | 6 weeks CGI | 8 weeks CGI | 10 weeks CGI | 12 weeks CGI | 14 weeks CGI | 16 weeks CGI | 18 weeks CGI | 20 weeks CGI | 22 weeks CGI | 24 weeks CGI | |
| First Open Label DCS | 4 | 2 | 2 | 2 | 2 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 3 | 2.5 | 2 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline CGI for first intervention | 2 weeks CGI for first intervention | 4 weeks CGI for first intervention | 6 weeks CGI for first intervention | Baseline CGI for second intervention | 2 weeks CGI for second intervention | 4 weeks CGI for second intervention | 6 weeks CGI for second intervention | |
| DCS First, Then Placebo | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 |
| Placebo First, Then DCS | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline HAM | 2 weeks HAM | 4 weeks HAM | 6 weeks HAM | 8 weeks HAM | 10 weeks HAM | 12 weeks HAM | 14 weeks HAM | 16 weeks HAM | 18 weeks HAM | 20 weeks HAM | 22 weeks HAM | 24 weeks HAM | |
| First Open Label DCS | 5 | 1.5 | 1 | 0.5 | 1.5 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 0.5 | 1 | 1 | 0 | 2.5 | 0 | 0 | 0 | 3.5 | 0 | 0 | 0 | 0 |
Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline HAM for first intervention | 2 weeks HAM for first intervention | 4 weeks HAM for first intervention | 6 weeks HAM for first intervention | Baseline HAM for second intervention | 2 weeks HAM for second intervention | 4 weeks HAM for second intervention | 6 weeks HAM for second intervention | |
| DCS First, Then Placebo | 0 | 1 | 0 | 0 | 2 | 12 | 9 | 2 |
| Placebo First, Then DCS | 4 | 5 | 2 | 10 | 0 | 0 | 0 | 0 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline YMRS | 2 weeks YMRS | 4 weeks YMRS | 6 weeks YMRS | 8 weeks YMRS | 10 weeks YMRS | 12 weeks YMRS | 14 weeks YMRS | 16 weeks YMRS | 18 weeks YMRS | 20 weeks YMRS | 22 weeks YMRS | 24 weeks YMRS | |
| First Open Label DCS | 2 | 1 | 1 | 0 | 0 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline YMRS for first intervention | 2 weeks YMRS for first intervention | 4 weeks YMRS for first intervention | 6 weeks YMRS for first intervention | Baseline YMRS for second intervention | 2 weeks YMRS for second intervention | 4 weeks YMRS for second intervention | 6 weeks YMRS for second intervention | |
| DCS First, Then Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo First, Then DCS | 1 | 0 | 0 | 0 | 4 | 1 | 1 | 1 |
Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution, standard deviation of 10. Higher scores signify better functioning. (NCT02304432)
Timeframe: Baseline and Week 8 of open-label DCS treatment
| Intervention | T scores (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Processing Speed | Baseline Attention/Vigilance | Baseline Working Memory | Baseline Verbal Learning | Baseline Visual Learning | Baseline Reasoning/Problem Solving | Baseline Social Cognition | Baseline Overall Composite Score | Week 8 of open-label DCS Processing Speed | Week 8 of open-label DCS Attention/Vigilance | Week 8 of open-label DCS Working Memory | Week 8 of open-label DCS Verbal Learning | Week 8 of open-label DCS Visual Learning | Week 8 of open-label DCS Reasoning/Problem Solving | Week 8 of open-label DCS Social Cognition | Week 8 of open-label DCS Overall Composite Score | |
| Open Label DCS | 48.5 | 44.5 | 38.5 | 54 | 50.5 | 52.5 | 48 | 46.5 | 52.5 | 47.5 | 50.5 | 43.5 | 54.5 | 66.5 | 44.5 | 51.5 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline positive | Baseline negative | 2 weeks positive | 2 weeks negative | 4 weeks positive | 4 weeks negative | 6 weeks positive | 6 weeks negative | 8 weeks positive | 8 weeks negative | 10 weeks positive | 10 weeks negative | 12 weeks positive | 12 weeks negative | 14 weeks positive | 14 weeks negative | 16 weeks positive | 16 weeks negative | 18 weeks positive | 18 weeks negative | 20 weeks positive | 20 weeks negative | 22 weeks positive | 22 weeks negative | 24 weeks positive | 24 weeks negative | |
| First Open Label DCS | 14.5 | 14.5 | 10 | 12 | 10.5 | 12 | 9 | 12 | 9 | 12 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 11 | 14 | 11 | 14 | 10.5 | 13.5 | 9 | 13 | 9.5 | 12 | 10.5 | 13 | 11 | 12 | 10 | 12 | 10.5 | 12 | 10.5 | 12 | 10.5 | 12 | 9.5 | 12 | 10 | 12 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline positive for first intervention | Baseline negative symptoms for first intervention | 2 weeks positive for first intervention | 2 weeks negative for first intervention | 4 weeks positive for first intervention | 4 weeks negative for first intervention | 6 weeks positive for first intervention | 6 weeks negative for first intervention | Baseline positive for second intervention | Baseline negative for second intervention | 2 weeks positive for second intervention | 2 weeks negative for second intervention | 4 weeks positive for second intervention | 4 weeks negative for second intervention | 6 weeks positive for second intervention | 6 weeks negative for second intervention | |
| DCS First, Then Placebo | 10 | 15 | 10 | 15 | 10 | 15 | 10 | 15 | 15 | 18 | 15 | 18 | 15 | 18 | 14 | 18 |
| Placebo First, Then DCS | 11 | 9 | 12 | 15 | 11 | 13 | 13 | 13 | 13 | 13 | 10 | 11 | 9 | 11 | 9 | 11 |
The NIHSS score ranges from 0 (best score) to 42 (worst score). (NCT00414726)
Timeframe: 4 hours after starting treatment
| Intervention | 0-4 hour change in NIHSS score (Mean) |
|---|---|
| Normobaric Oxygen | -0.37 |
| Room Air | -0.43 |
The NIHSS score ranges from 0 (best score) to 42 (worst score). (NCT00414726)
Timeframe: 24 hours
| Intervention | 0-24 hour change in NIHSS score (Mean) |
|---|---|
| Normobaric Oxygen | 0.17 |
| Room Air | -0.73 |
3 reviews available for aspartic acid and Acute Disease
| Article | Year |
|---|---|
N-acetylaspartate decrease in acute stage of ischemic stroke: a perspective from experimental and clinical studies.
Topics: Acute Disease; Animals; Aspartic Acid; Brain; Brain Ischemia; Humans; Magnetic Resonance Spectroscop | 2015 |
Role of endogenous excitatory amino acid neurotransmitters in the pathogenesis and evolution of acute brain injury.
Topics: Acute Disease; Amino Acids; Animals; Aspartic Acid; Brain Diseases; Brain Injuries; Calcium; Calcium | 1989 |
Isozymes of aspartate aminotransferase in tissues and blood of man.
Topics: Acute Disease; Adult; Aging; Alpha-Globulins; Animals; Aspartate Aminotransferases; Aspartic Acid; B | 1966 |
8 trials available for aspartic acid and Acute Disease
| Article | Year |
|---|---|
Effect of oral arginine supplementation on exhaled nitric oxide concentration in sickle cell anemia and acute chest syndrome.
Topics: Acute Chest Syndrome; Acute Disease; Administration, Oral; Adolescent; Anemia, Sickle Cell; Arginine | 2010 |
Metabolic counterpart of decreased apparent diffusion coefficient during hyperacute ischemic stroke: a brain proton magnetic resonance spectroscopic imaging study.
Topics: Acute Disease; Adult; Aged; Aspartic Acid; Brain; Brain Ischemia; Cerebrovascular Circulation; Diffu | 2003 |
Magnetic resonance spectroscopy study of oxygen therapy in ischemic stroke.
Topics: Acute Disease; Aged; Aged, 80 and over; Aspartic Acid; Brain; Brain Ischemia; Diffusion Magnetic Res | 2007 |
[Clinical application of 1H nuclear magnetic resonance spectroscopy into patients with cerebral ischemia].
Topics: Acute Disease; Aged; Aged, 80 and over; Aspartic Acid; Brain; Cerebral Infarction; Female; Humans; L | 1998 |
Regression analysis of metabolite concentrations estimated from localized proton MR spectra of active and chronic multiple sclerosis lesions.
Topics: Acute Disease; Adult; Aged; Aspartic Acid; Brain; Chronic Disease; Contrast Media; Creatine; Female; | 2000 |
Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Alanine; Amino Acids; Aspartic Acid; Biomarkers; Chol | 2001 |
[Therapy of acute and chronic hepatitis. A clinical study using Inzolen infusion AM].
Topics: Acute Disease; Aspartic Acid; Chronic Disease; Clinical Trials as Topic; Female; Hepatitis; Humans; | 1979 |
[On the therapy of liver diseases with ornithine aspartate].
Topics: Acute Disease; Alanine Transaminase; Ammonia; Aspartic Acid; Bilirubin; Cholangitis; Chronic Disease | 1969 |
63 other studies available for aspartic acid and Acute Disease
| Article | Year |
|---|---|
A Case of Autoimmune Hepatitis/Primary Biliary Cholangitis Overlap Syndrome during Treatment with Brodalumab for Generalized Pustular Psoriasis.
Topics: Acute Disease; Aged; Alanine Transaminase; Antibodies, Monoclonal, Humanized; Aspartic Acid; Autoant | 2021 |
Sodium pyruvate improves the plasma amino acid profile in rats with L-arginine-induced acute pancreatitis.
Topics: Acute Disease; Adenosine Triphosphate; Amino Acids; Animals; Arginine; Aspartic Acid; Pancreatitis; | 2023 |
Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus.
Topics: Acute Disease; Amino Acids; Animals; Anticonvulsants; Aspartic Acid; Bridged Bicyclo Compounds, Hete | 2014 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Case-Control Studies; Cerebral Co | 2008 |
Hypothermia reduces cytotoxic edema and metabolic alterations during the acute phase of massive SAH: a diffusion-weighted imaging and spectroscopy study in rats.
Topics: Acute Disease; Animals; Aspartic Acid; Body Temperature; Brain; Brain Edema; Cerebral Cortex; Creati | 2008 |
Metabolism of DWI lesions: implications for rescue therapy.
Topics: Acute Disease; Animals; Aspartic Acid; Cell Hypoxia; Cerebrovascular Circulation; Diffusion Magnetic | 2007 |
Associations between diffusion and perfusion parameters, N-acetyl aspartate, and lactate in acute ischemic stroke.
Topics: Acute Disease; Aspartic Acid; Brain Ischemia; Cell Death; Cerebrovascular Circulation; Diffusion Mag | 2009 |
[Effect of a simple morphine system injection in some aminoacids in the anterior cingulate cortex during acute pain].
Topics: Acute Disease; Amino Acids; Analgesics, Opioid; Animals; Arginine; Aspartic Acid; Cerebral Cortex; D | 2008 |
Neurometabolic changes in the acute phase after sports concussions correlate with symptom severity.
Topics: Acute Disease; Adult; Aspartic Acid; Athletic Injuries; Brain; Brain Concussion; Cognition Disorders | 2010 |
Time-resolved functional 1H MR spectroscopic detection of glutamate concentration changes in the brain during acute heat pain stimulation.
Topics: Acute Disease; Adult; Aspartic Acid; Cerebral Cortex; Choline; Creatine; Glutamic Acid; Hot Temperat | 2010 |
Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy.
Topics: Acute Disease; Adult; Animals; Anxiety; Anxiety Disorders; Aspartic Acid; Choline; Diagnostic and St | 2010 |
Effects of acute and chronic hyperglycemia on the neurochemical profiles in the rat brain with streptozotocin-induced diabetes detected using in vivo ¹H MR spectroscopy at 9.4 T.
Topics: Acute Disease; Algorithms; Animals; Aspartic Acid; Biological Transport, Active; Blood Glucose; Bloo | 2012 |
Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex.
Topics: Acute Disease; Adult; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Female; Glutamic Acid; Glu | 2003 |
Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events.
Topics: Acute Disease; Adult; Aged; Alleles; Amino Acid Substitution; Aspartic Acid; Case-Control Studies; C | 2003 |
Effects of acute hypoxic conditions on extracellular excitatory amino acids and dopamine in the striatum of freely-moving rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acute Disease; Animals; Aspartic Acid; Corpus Striatum; Dopamine; Ex | 2003 |
A prospective longitudinal in vivo 1H MR spectroscopy study of the SIV/macaque model of neuroAIDS.
Topics: Acute Disease; AIDS Dementia Complex; Animals; Aspartic Acid; Brain; Choline; Chronic Disease; Creat | 2004 |
In vivo 1H MRS of brain injury and repair during acute SIV infection in the macaque model of neuroAIDS.
Topics: Acute Disease; AIDS Dementia Complex; Animals; Aspartic Acid; Brain; Choline; Creatine; Female; Fron | 2004 |
Multiple spin-echo spectroscopic imaging for rapid quantitative assessment of N-acetylaspartate and lactate in acute stroke.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Analysis of Variance; Aspartic Acid; Case-Control Stu | 2004 |
A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania.
Topics: Acute Disease; Adult; Antimanic Agents; Antipsychotic Agents; Aspartic Acid; Bipolar Disorder; Choli | 2005 |
Carbon monoxide brain toxicity: clinical, magnetic resonance imaging, magnetic resonance spectroscopy, and neuropsychological effects in 9 people.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Basal Ganglia; Brain; Carbon Monoxide Poisoning; Ch | 2005 |
Intestinal ischemia-reperfusion injury does not lead to acute central nervous system damage.
Topics: Acute Disease; Animals; Aspartic Acid; Brain; Brain Diseases; Gangrene; Intestinal Mucosa; Intestine | 2005 |
The impact of acute hypoglycemia on neuropsychological and neurometabolite profiles in children with type 1 diabetes.
Topics: Acute Disease; Aspartic Acid; Attention; Blood Glucose; Child; Diabetes Mellitus, Type 1; Female; Fo | 2005 |
Study of hypothalamic metabolism in cluster headache by proton MR spectroscopy.
Topics: Acute Disease; Adult; Aged; Aspartic Acid; Biomarkers; Cerebral Cortex; Chronic Disease; Cluster Hea | 2006 |
Endothelial nitric oxide synthase Glu298Asp gene polymorphism in periodontal diseases.
Topics: Acute Disease; Adolescent; Adult; Amino Acid Substitution; Aspartic Acid; Chi-Square Distribution; C | 2006 |
+H-proton-magnetic resonance spectroscopic findings in a patient with acute hemicerebellitis presenting without localized signs: a case report.
Topics: Acute Disease; Adolescent; Aspartic Acid; Cerebellar Diseases; Choline; Cranial Fossa, Posterior; Cr | 2006 |
HFE gene mutations in patients with acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspartic Acid; Female; Genotype; Hemochro | 2006 |
[Extracellular aminoacids in the amygdala and nucleus accumbens in the rat during acute pain].
Topics: Acute Disease; Amygdala; Animals; Arginine; Aspartic Acid; Glutamic Acid; Male; Nucleus Accumbens; P | 2007 |
Magnetic resonance spectroscopy features of normal-appearing white matter in patients with acute brucellosis.
Topics: Acute Disease; Adolescent; Adult; Aspartic Acid; Brain Diseases; Brucellosis; Case-Control Studies; | 2008 |
Intermediary metabolism, Na+, the low calcium-response, and acute disease.
Topics: Acute Disease; Animals; Aspartic Acid; Bacteriological Techniques; Calcium; Culture Media, Serum-Fre | 2007 |
[Effects of acute ammonia poisoning on cerebral amino acids metabolism in rats].
Topics: Acute Disease; Amino Acids; Ammonia; Animals; Aspartic Acid; Brain; Glutamates; Glutamic Acid; Male; | 1984 |
[Electrocardiographic localization of myocardial infarct and the activity of various blood serum enzymes in the acute stage of the disease].
Topics: Acute Disease; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Aspartic Acid; Clinic | 1980 |
Cerebral metabolites in patients with acute and subacute strokes: concentrations determined by quantitative proton MR spectroscopy.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain; Cerebrovascular Dis | 1995 |
Metabolic changes in acute and subacute cerebral infarctions: findings at proton MR spectroscopic imaging.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain; Cerebral Infarction; Choline; C | 1995 |
[Magnetic resonance spectroscopy of acute cerebral infarctions].
Topics: Acute Disease; Adult; Aged; Aspartic Acid; Cerebral Infarction; Choline; Creatine; Humans; Magnetic | 1993 |
Reversible decreases in N-acetylaspartate after acute brain injury.
Topics: Acute Disease; Aspartic Acid; Brain; Demyelinating Diseases; Humans; Magnetic Resonance Spectroscopy | 1995 |
Evolution of acute focal cerebral ischaemia in rats observed by localized 1H MRS, diffusion-weighted MRI, and electrophysiological monitoring.
Topics: Acute Disease; Animals; Aspartic Acid; Brain Ischemia; Electroencephalography; Electrophysiology; Ma | 1995 |
Proton MR spectroscopy in acute middle cerebral artery stroke.
Topics: Acute Disease; Aged; Artifacts; Aspartic Acid; Brain Ischemia; Cerebral Arteries; Cerebral Infarctio | 1996 |
Release of excitatory and inhibitory amino acids from the locus coeruleus of conscious rats by cardiovascular stimuli and various forms of acute stress.
Topics: Acute Disease; Amino Acids; Animals; Antihypertensive Agents; Arginine; Aspartic Acid; Cardiovascula | 1995 |
[From the study of biochemical changes in ischemic and reperfused skeletal muscle to the controlled reperfusion of limbs in patients with acute severe ischemia].
Topics: Acute Disease; Aged; Aged, 80 and over; Alkalies; Aspartic Acid; Biochemical Phenomena; Biochemistry | 1998 |
Studies of acute ischemic stroke with proton magnetic resonance spectroscopy: relation between time from onset, neurological deficit, metabolite abnormalities in the infarct, blood flow, and clinical outcome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain; Brain Chemistry; Brain Edema; B | 1998 |
Central modulation of formalin-induced acute peripheral inflammation & pain by some putative amino acid neurotransmitters in rats.
Topics: Acute Disease; Amino Acids; Animals; Aspartic Acid; Brain; Formaldehyde; gamma-Aminobutyric Acid; In | 1998 |
N-Acetylaspartate distribution in rat brain striatum during acute brain ischemia.
Topics: Acute Disease; Animals; Aspartic Acid; Brain Ischemia; Cerebral Infarction; Corpus Striatum; Magneti | 1999 |
[Levels of neurotransmitter amino acids in the cerebrospinal fluid of patients with acute ischemic stroke].
Topics: Acute Disease; Aspartic Acid; Brain Ischemia; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glycin | 1999 |
Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation.
Topics: Acute Disease; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Pre | 1999 |
In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis.
Topics: Acute Disease; Adult; Aspartic Acid; Axons; Brain; Creatine; Female; Follow-Up Studies; Humans; Magn | 1999 |
N-acetylaspartate distribution in proton spectroscopic images of ischemic stroke: relationship to infarct appearance on T2-weighted magnetic resonance imaging.
Topics: Acute Disease; Aspartic Acid; Brain; Brain Ischemia; Cerebral Infarction; Humans; Image Processing, | 2000 |
Proton MR spectroscopy in patients with acute temporal lobe seizures.
Topics: Acute Disease; Adult; Aspartic Acid; Creatine; Epilepsy, Temporal Lobe; Hippocampus; Humans; Lactic | 2001 |
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Topics: Acute Disease; Amino Acid Substitution; Animals; Aspartic Acid; Cell Division; Cell Line; Cell Trans | 2001 |
N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury.
Topics: 2,2'-Dipyridyl; Acute Disease; Animals; Aspartic Acid; Biomarkers; Brain Chemistry; Brain Edema; Bra | 2001 |
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Aspartic Acid; Case-Control Stud | 2001 |
Carbohydrate and amino acid metabolism in rat cerebral cortex in moderate and extreme hypercapnia.
Topics: Acute Disease; Alanine; Amino Acids; Ammonia; Anesthesia, General; Animals; Asparagine; Aspartic Aci | 1975 |
[Use of panangin, obsidan and isoptin in acute rhythm disorders under conditions of cardiological first aid service].
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspartic Acid; | 1976 |
Early time course of N-acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain Chemistry; Cerebrovascular Circu | 1992 |
Amino acid release from cerebral cortex in experimental acute liver failure, studied by in vivo cerebral cortex microdialysis.
Topics: Acute Disease; Amino Acids; Animals; Aspartic Acid; Cerebral Cortex; Dialysis; gamma-Aminobutyric Ac | 1992 |
Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques.
Topics: Acute Disease; Adult; Aspartic Acid; Biopsy; Brain Chemistry; Brain Neoplasms; Choline; Creatine; De | 1992 |
Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis.
Topics: Acute Disease; Adult; Aspartic Acid; Brain; Choline; Chronic Disease; Female; Humans; Lipid Metaboli | 1991 |
Increased aspartic acid release from the iron-induced epileptogenic focus.
Topics: Acute Disease; Animals; Aspartic Acid; Chronic Disease; Epilepsy; Glutamates; Glutamic Acid; Iron; M | 1990 |
[Arrhythmias in acute myocardial infarct].
Topics: Acidosis; Acute Disease; Arrhythmias, Cardiac; Aspartic Acid; Atrial Fibrillation; Atrial Flutter; B | 1973 |
[Magnesium metabolism in acute magnesium deficiency following parenteral administration of magnesium chloride and aspartate in long-term studies of rats].
Topics: Acute Disease; Animals; Aspartic Acid; Chlorides; Infusions, Parenteral; Magnesium; Magnesium Defici | 1974 |
[Effect of L-aspartic acid on the carbohydrate-phosphorus metabolism of the heart muscle in the acute period of experimental myocardial infarct].
Topics: Acute Disease; Aerobiosis; Animals; Aspartic Acid; Carbohydrate Metabolism; Glycolysis; Heart; Isoen | 1972 |
On the mechanism of ketogenesis and its control. I. On a possible role of acetoacetyl-CoA thiolase in the control of ketone body production.
Topics: Acetates; Acetoacetates; Acetyltransferases; Acute Disease; Animals; Aspartic Acid; Carbon Radioisot | 1973 |
l-asparaginase resistance in human leukemia--asparagine synthetase.
Topics: Acute Disease; Asparaginase; Asparagine; Aspartic Acid; Carbon Isotopes; Chromatography; Chronic Dis | 1969 |
[Experimental study on the selective intracoronary infusion, with special reference to its effect on acute coronary stenosis].
Topics: Acute Disease; Animals; Aspartic Acid; Cardiac Catheterization; Cardiac Output; Coronary Disease; Co | 1968 |